Afatinib Osimertinib Sequencing NIS

Sponsor
Boehringer Ingelheim
Study ID
NCT03370770
Status
Completed

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Afatinib — DRUG
    GILOTRIF, GIOTRIF, XOVOLTIB
  • Osimertinib — DRUG
    on T790M resistance mutation was developed

Study Details

This is a non-interventional, multi-country, multi-centre cohort study based on existing data from medical records of patients with EGFR mutation-positive advanced NSCLC treated with afatinib (Gi(l)otrif®) as the first-line treatment followed by osimertinib in case the T790M resistance mutation was developed.

Key Dates

Start date
Dec 28, 2017
Status verified
Dec 2020
Primary completion
Nov 28, 2019
Completion
Nov 28, 2019

Study Design

Enrollment
204 participants (actual)

Arms

  • Arm: patients with EGFR mutation-positive NSCLC
    (Non-Small Cell Lung Cancer) (Epidermal Growth Factor Receptor)

Primary Outcome Measure

Time on Treatment With Afatinib (Gi(l)Otrif®) Followed by Osimertinib [ Time Frame: Data collected from start of treatment until data entry completion, up to 96.8 months for first analysis and up to 114.1 months for the extension analysis. ]

Related Studies